A few case reports suggested that lenalidomide may be efficacious in MDS with DDX41 mutations, which could be related to the localization of DDX41 in chr.5q35, which is likely to be deleted in the 5q- subset of patients (40, 41). This evidence concerns the gene DDX41 and myelodysplastic syndrome.